|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
US4634665A
(en)
|
1980-02-25 |
1987-01-06 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
US5179017A
(en)
|
1980-02-25 |
1993-01-12 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
CA1208546A
(en)
|
1981-09-08 |
1986-07-29 |
Anthony Cerami |
Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
|
|
US4510245A
(en)
|
1982-11-18 |
1985-04-09 |
Chiron Corporation |
Adenovirus promoter system
|
|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
|
EP0154316B1
(en)
|
1984-03-06 |
1989-09-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified lymphokine and production thereof
|
|
US5672347A
(en)
|
1984-07-05 |
1997-09-30 |
Genentech, Inc. |
Tumor necrosis factor antagonists and their use
|
|
IL73883A
(en)
|
1984-12-20 |
1990-12-23 |
Yeda Res & Dev |
Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
|
|
US5168062A
(en)
|
1985-01-30 |
1992-12-01 |
University Of Iowa Research Foundation |
Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
|
|
EP0613006A1
(en)
|
1985-08-16 |
1994-08-31 |
The Rockefeller University |
Antibodies to cachectin and immunoassays
|
|
US4968615A
(en)
|
1985-12-18 |
1990-11-06 |
Ciba-Geigy Corporation |
Deoxyribonucleic acid segment from a virus
|
|
EP0230574A3
(en)
|
1986-01-31 |
1989-03-22 |
Yale University |
Pharmaceutical compositions against infections caused by lav/htlv iii virus and the use thereof
|
|
DE3631229A1
(de)
|
1986-09-13 |
1988-03-24 |
Basf Ag |
Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
|
|
JP2638652B2
(ja)
|
1988-07-18 |
1997-08-06 |
カイロン・コーポレーション |
カケクチンと反応するモノクロナール抗体
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
DE68914244T2
(de)
|
1988-10-24 |
1994-10-27 |
Otsuka Pharma Co Ltd |
Monoklonaler Antikörper.
|
|
EP0374510B1
(en)
|
1988-12-19 |
1997-01-15 |
American Cyanamid Company |
Products for the treatment of endotoxic shock in a mammal
|
|
JP2989002B2
(ja)
|
1988-12-22 |
1999-12-13 |
キリン―アムジエン・インコーポレーテツド |
化学修飾顆粒球コロニー刺激因子
|
|
CA2003981C
(en)
|
1988-12-27 |
2000-06-13 |
Hiroshi Ishimaru |
Pharmaceutical compositions and use thereof in the treatment of psoriasis
|
|
US6448380B2
(en)
|
1989-08-07 |
2002-09-10 |
Peptech Limited |
Tumor necrosis factor antibodies
|
|
US5959087A
(en)
|
1989-08-07 |
1999-09-28 |
Peptide Technology, Ltd. |
Tumour necrosis factor binding ligands
|
|
JP3443119B2
(ja)
|
1989-08-07 |
2003-09-02 |
ペプテック リミテッド |
腫瘍壊死因子結合リガンド
|
|
FR2651130B1
(fr)
|
1989-08-23 |
1991-12-13 |
Roussel Uclaf |
Sequence d'oligonucleotides anti-sens, anti-arn message du tnf alpha, procede de preparation, application a titre de medicaments et compositions pharmaceutiques.
|
|
AU630497B2
(en)
|
1989-09-05 |
1992-10-29 |
Immunex Corporation |
Tumor necrosis factor-alpha and -beta receptors
|
|
GB8921123D0
(en)
|
1989-09-19 |
1989-11-08 |
Millar Ann B |
Treatment of ards
|
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
|
DE4037604A1
(de)
|
1990-04-25 |
1991-10-31 |
Bayer Ag |
Verwendung von anti-tnf-antikoerpern als arzneimittel bei der behandlung von ischaemien und deren folgen
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
GB9014932D0
(en)
|
1990-07-05 |
1990-08-22 |
Celltech Ltd |
Recombinant dna product and method
|
|
JPH06508511A
(ja)
|
1990-07-10 |
1994-09-29 |
ケンブリッジ アンティボディー テクノロジー リミティド |
特異的な結合ペアーの構成員の製造方法
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
DE69129154T2
(de)
|
1990-12-03 |
1998-08-20 |
Genentech, Inc., South San Francisco, Calif. |
Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
|
|
US5994510A
(en)
|
1990-12-21 |
1999-11-30 |
Celltech Therapeutics Limited |
Recombinant antibodies specific for TNFα
|
|
GB2279077B
(en)
|
1990-12-21 |
1995-06-14 |
Celltech Ltd |
Therapeutic compositions comprising recombinant antibodies specific for the TNFalpha
|
|
GB9109645D0
(en)
|
1991-05-03 |
1991-06-26 |
Celltech Ltd |
Recombinant antibodies
|
|
GB9028123D0
(en)
|
1990-12-28 |
1991-02-13 |
Erba Carlo Spa |
Monoclonal antibodies against human tumor necrosis factor alpha
|
|
DE69233769D1
(de)
|
1991-03-01 |
2009-09-24 |
Dyax Corp |
Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
|
|
DE69233069T2
(de)
|
1991-03-15 |
2003-11-27 |
Amgen Inc., Thousand Oaks |
Pegylation von polypeptiden
|
|
US7192584B2
(en)
|
1991-03-18 |
2007-03-20 |
Centocor, Inc. |
Methods of treating psoriasis with anti-TNF antibodies
|
|
EP1097945B1
(en)
|
1991-03-18 |
2007-07-04 |
New York University |
Monoclonal and chimeric antibody specific for human tumor necrosis factor
|
|
US6277969B1
(en)
|
1991-03-18 |
2001-08-21 |
New York University |
Anti-TNF antibodies and peptides of human tumor necrosis factor
|
|
US20040120952A1
(en)
|
2000-08-07 |
2004-06-24 |
Centocor, Inc |
Anti-TNF antibodies and peptides of human tumor necrosis factor
|
|
US20070298040A1
(en)
|
1991-03-18 |
2007-12-27 |
Centocor, Inc. |
Methods of treating seronegative arthropathy with anti-TNF antibodies
|
|
US5656272A
(en)
|
1991-03-18 |
1997-08-12 |
New York University Medical Center |
Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
|
|
US20060246073A1
(en)
|
1991-03-18 |
2006-11-02 |
Knight David M |
Anti-TNF antibodies and peptides of human tumor necrosis factor
|
|
ATE171471T1
(de)
|
1991-03-29 |
1998-10-15 |
Immunex Corp |
Isolierte virale proteine als cytokinantagonisten
|
|
ATE414768T1
(de)
|
1991-04-10 |
2008-12-15 |
Scripps Research Inst |
Bibliotheken heterodimerer rezeptoren mittels phagemiden
|
|
DE4122599C2
(de)
|
1991-07-08 |
1993-11-11 |
Deutsches Krebsforsch |
Phagemid zum Screenen von Antikörpern
|
|
ATE181571T1
(de)
|
1991-09-23 |
1999-07-15 |
Medical Res Council |
Methoden zur herstellung humanisierter antikörper
|
|
AU3244693A
(en)
|
1991-12-17 |
1993-07-19 |
Schering Corporation |
Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock
|
|
US5605923A
(en)
|
1992-04-02 |
1997-02-25 |
Smithkline Beecham Corporation |
Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor
|
|
EP0585705B1
(en)
|
1992-08-28 |
1998-11-04 |
Bayer Corporation |
Use of monoclonal antibodies to TNF to treat bacterial meningitis
|
|
JPH07504203A
(ja)
|
1992-09-15 |
1995-05-11 |
イミュネックス・コーポレーション |
腫瘍壊死因子アンタゴニストを用いるｔｎｆ−依存性炎症の治療方法
|
|
US6270766B1
(en)
|
1992-10-08 |
2001-08-07 |
The Kennedy Institute Of Rheumatology |
Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
|
|
WO1994008609A1
(en)
|
1992-10-15 |
1994-04-28 |
Dana-Farber Cancer Institute, Inc. |
TREATMENT OF INSULIN RESISTANCE IN OBESITY LINKED TYPE II DIABETES USING ANTAGONISTS TO TNF-α FUNCTION
|
|
US5888511A
(en)
|
1993-02-26 |
1999-03-30 |
Advanced Biotherapy Concepts, Inc. |
Treatment of autoimmune diseases, including AIDS
|
|
DE69427928T3
(de)
|
1993-03-05 |
2012-05-10 |
Bayer Healthcare Llc |
Humane monoklonale anti-TNF alpha Antikörper
|
|
ATE183513T1
(de)
|
1993-06-03 |
1999-09-15 |
Therapeutic Antibodies Inc |
Herstellung von antikörperfragmenten
|
|
EP0659766A1
(en)
|
1993-11-23 |
1995-06-28 |
Schering-Plough |
Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
|
|
NZ278607A
(en)
|
1994-02-07 |
1999-05-28 |
Knoll Ag |
Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
|
|
WO1995023813A1
(en)
|
1994-03-04 |
1995-09-08 |
Merck & Co., Inc. |
In vitro antibody affinity maturation using alanine scanning mutagenesis
|
|
CN1153530A
(zh)
*
|
1995-03-09 |
1997-07-02 |
比奥美希奥公司 |
相关于类风湿性关节炎的msrv-1病毒和致病性和/或感染性msrv-2因子
|
|
AU2365795A
(en)
|
1995-04-20 |
1996-11-07 |
Centocor Inc. |
Multiple administrations of anti-tnf antibody
|
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
|
DE122004000004I1
(de)
|
1996-02-09 |
2004-08-12 |
Abott Biotechnology Ltd |
Humane Antikörper welche an Humanen TNFalpha binden.
|
|
DE69709493T2
(de)
|
1996-06-27 |
2002-10-31 |
Pfizer Inc., New York |
Substituierte Indazolderivate
|
|
JP2000516594A
(ja)
|
1996-07-26 |
2000-12-12 |
スミスクライン・ビーチャム・コーポレイション |
免疫細胞介在全身性疾患の改良された治療法
|
|
ATE242234T1
(de)
|
1996-11-15 |
2003-06-15 |
Darwin Discovery Ltd |
Bicyclische arylcarboxamide und ihre therapeutische verwendung
|
|
ES2264569T3
(es)
|
1997-04-15 |
2007-01-01 |
Pharmexa A/S |
Moleculas de tnf-alfa modificadas, adn que codifica dichas moleculas de tnf-alfa modificadas y vacunas que comprenden dichas moleculas de tnf-alfa y adn.
|
|
US20040009166A1
(en)
*
|
1997-04-30 |
2004-01-15 |
Filpula David R. |
Single chain antigen-binding polypeptides for polymer conjugation
|
|
JP2001525816A
(ja)
|
1997-05-12 |
2001-12-11 |
ザ ケネディー インスティチュート オブ リューマトロジー |
治療における腫瘍壊死因子アルファおよび血管内皮成長因子の抑制
|
|
DE19734293A1
(de)
|
1997-08-08 |
1999-02-11 |
Boehringer Mannheim Gmbh |
Verwendung von pharmazeutischen Kombinationspräparaten enthaltend Erythropoietin und Eisenpräparate zur Behandlung von rheumatischen Erkrankungen
|
|
JPH11127882A
(ja)
|
1997-10-27 |
1999-05-18 |
Nippon Kayaku Co Ltd |
新規生理活性物質ｎｋ３０４２４ａ，ｎｋ３０４２４ｂ，それらの製造法およびそれらの用途
|
|
US6379666B1
(en)
|
1999-02-24 |
2002-04-30 |
Edward L. Tobinick |
TNF inhibitors for the treatment of neurological, retinal and muscular disorders
|
|
US6177077B1
(en)
|
1999-02-24 |
2001-01-23 |
Edward L. Tobinick |
TNT inhibitors for the treatment of neurological disorders
|
|
US20030113318A1
(en)
|
1999-02-24 |
2003-06-19 |
Tobinick Edward Lewis |
TNF inhibition for the treatment of pre-menstrual syndrome and primary dysmenorrhea
|
|
US6419944B2
(en)
|
1999-02-24 |
2002-07-16 |
Edward L. Tobinick |
Cytokine antagonists for the treatment of localized disorders
|
|
US6423321B2
(en)
|
1999-02-24 |
2002-07-23 |
Edward L. Tobinick |
Cytokine antagonists for the treatment of sensorineural hearing loss
|
|
US6537549B2
(en)
|
1999-02-24 |
2003-03-25 |
Edward L. Tobinick |
Cytokine antagonists for the treatment of localized disorders
|
|
EP1041072B1
(en)
|
1999-03-31 |
2003-07-16 |
Pfizer Products Inc. |
Dioxocyclopentyl hydroxamic acids
|
|
WO2000062790A2
(en)
|
1999-04-19 |
2000-10-26 |
Immunex Corporation |
Soluble tumor necrosis factor receptor treatment of medical disorders
|
|
US20010021380A1
(en)
|
1999-04-19 |
2001-09-13 |
Pluenneke John D. |
Soluble tumor necrosis factor receptor treatment of medical disorders
|
|
KR20020008186A
(ko)
|
1999-05-11 |
2002-01-29 |
다우 케네드 제이. |
에리트로포이에틴 투여의 약동학 및 약역학 모델링
|
|
EP1189628A1
(en)
|
1999-06-24 |
2002-03-27 |
Pharmacia Corporation |
Combination of tumor necrosis factor (tnf) antagonists and cox-2 inhibitors for the treatment of inflammation
|
|
ATE389414T1
(de)
|
1999-09-08 |
2008-04-15 |
Chugai Pharmaceutical Co Ltd |
Stabile proteinlösung abgefüllt in einem behältnis aus hydrophobem harz und eine methode zur stabilisierung derselben
|
|
AU3082401A
(en)
|
1999-11-24 |
2001-06-04 |
Centocor Inc. |
Therapy of psoriasis
|
|
EP1237575B1
(en)
|
1999-12-14 |
2008-08-06 |
Genentech, Inc. |
Tnf-alpha antagonist and lfa-1 antagonist for treating rheumatoid arthritis
|
|
AR026801A1
(es)
|
2000-01-12 |
2003-02-26 |
Medidom Lab |
Sustancias para uso en el tratamiento de la psoriasis
|
|
JP4812921B2
(ja)
|
2000-04-14 |
2011-11-09 |
田辺三菱製薬株式会社 |
ベーチェット病治療剤
|
|
GB0013810D0
(en)
|
2000-06-06 |
2000-07-26 |
Celltech Chiroscience Ltd |
Biological products
|
|
US7879328B2
(en)
|
2000-06-16 |
2011-02-01 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to B lymphocyte stimulator
|
|
US6984522B2
(en)
|
2000-08-03 |
2006-01-10 |
Regents Of The University Of Michigan |
Isolation and use of solid tumor stem cells
|
|
US20050249735A1
(en)
|
2000-08-07 |
2005-11-10 |
Centocor, Inc. |
Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
|
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
|
US20060018907A1
(en)
|
2000-08-07 |
2006-01-26 |
Centocor, Inc. |
Anti-TNF antibodies and peptides of human tumor necrosis factor
|
|
JP4731793B2
(ja)
|
2000-12-28 |
2011-07-27 |
アルセア テクノロジーズ インコーポレイテッド |
抗体全体またはそのフラグメントの結晶、ならびにこの結晶を作製および使用するための方法
|
|
US20030012786A1
(en)
|
2001-05-25 |
2003-01-16 |
Teoh Leah S. |
Use of anti-TNF antibodies as drugs in treating septic disorders of anemic patients
|
|
CA2385745C
(en)
|
2001-06-08 |
2015-02-17 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
|
AR035119A1
(es)
|
2001-08-16 |
2004-04-14 |
Lilly Co Eli |
Anticuerpos humanos antagonistas anti-htnfsf13b
|
|
PL217752B1
(pl)
|
2001-08-23 |
2014-08-29 |
Genmab As |
Izolowane ludzkie przeciwciało monoklonalne wobec IL-15 lub jego fragment wiążący antygen i związane z nimi hybrydoma, kompozycja farmaceutyczna oraz zastosowania medyczne
|
|
CA2463655A1
(en)
|
2001-10-15 |
2003-04-24 |
Chiron Corporation |
Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)
|
|
US20030161828A1
(en)
|
2002-02-19 |
2003-08-28 |
Abbott Gmbh & Co. Kg |
Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure
|
|
US20030206898A1
(en)
|
2002-04-26 |
2003-11-06 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
|
US20040009172A1
(en)
|
2002-04-26 |
2004-01-15 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
|
AR040603A1
(es)
|
2002-07-19 |
2005-04-13 |
Abbott Lab S A |
El uso de un anticuerpo anti-tnfalfa neutralizador de alta afinidad en la fabricacion de un medicamento y conjunto de elementos
|
|
US20090280065A1
(en)
|
2006-04-10 |
2009-11-12 |
Willian Mary K |
Uses and Compositions for Treatment of Psoriasis
|
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
|
US20040038874A1
(en)
|
2002-08-22 |
2004-02-26 |
Osemwota Omoigui |
Method of treatment of persistent pain
|
|
US7026301B2
(en)
|
2002-10-17 |
2006-04-11 |
New York University |
Method of orally treating inflammatory skin conditions with prodrugs of 5-fluorouracil
|
|
MY150740A
(en)
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
|
NZ540555A
(en)
|
2002-11-15 |
2008-04-30 |
Genmab As |
Antibody therapeutics for treatingand/or preventing diseases associated with cells expressing CD25, including autoimmune diseases, inflammatory and hyperproliferative skin disorders
|
|
US7807389B2
(en)
*
|
2003-03-14 |
2010-10-05 |
University Of Rochester |
Methods and compositions related to joint inflammation diseases
|
|
US7285256B2
(en)
|
2003-04-04 |
2007-10-23 |
Newmont Usa Limited |
Precious metal recovery using thiocyanate lixiviant
|
|
US7276478B2
(en)
|
2003-09-25 |
2007-10-02 |
Zymogenetics, Inc. |
Methods of treating autoimmune diseases using IL-21
|
|
TWI439284B
(zh)
|
2004-04-09 |
2014-06-01 |
Abbvie Biotechnology Ltd |
用於治療ＴＮＦα相關失調症之多重可變劑量療法
|
|
EP1807111A4
(en)
|
2004-10-08 |
2009-05-27 |
Abbott Biotech Ltd |
SYNCYTIAL RESPIRATORY VIRUS INFECTION (RSV)
|
|
AU2006246721B2
(en)
*
|
2005-05-16 |
2012-12-13 |
Abbvie Biotechnology Ltd |
Use of TNF inhibitor for treatment of erosive polyarthritis
|
|
US20070041905A1
(en)
|
2005-08-19 |
2007-02-22 |
Hoffman Rebecca S |
Method of treating depression using a TNF-alpha antibody
|
|
CA2626804A1
(en)
|
2005-11-01 |
2007-08-09 |
Abbott Biotechnology Ltd. |
Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
|
|
MX2008012896A
(es)
|
2006-04-05 |
2008-10-14 |
Abbott Biotech Ltd |
Purificacion de anticuerpos.
|
|
US20090317399A1
(en)
|
2006-04-10 |
2009-12-24 |
Pollack Paul F |
Uses and compositions for treatment of CROHN'S disease
|
|
WO2007120656A2
(en)
|
2006-04-10 |
2007-10-25 |
Abbott Biotechnology Ltd. |
Uses and compositions for treatment of rheumatoid arthritis
|
|
EP2666472A3
(en)
|
2006-04-10 |
2014-04-02 |
Abbott Biotechnology Ltd |
Uses and compositions for treatment of psoriatic arthritis
|
|
US9605064B2
(en)
|
2006-04-10 |
2017-03-28 |
Abbvie Biotechnology Ltd |
Methods and compositions for treatment of skin disorders
|
|
WO2007120626A2
(en)
|
2006-04-10 |
2007-10-25 |
Abbott Biotechnology Ltd. |
Uses and compositions for treatment of ankylosing spondylitis
|
|
US20080118496A1
(en)
|
2006-04-10 |
2008-05-22 |
Medich John R |
Uses and compositions for treatment of juvenile rheumatoid arthritis
|
|
US20080131374A1
(en)
|
2006-04-19 |
2008-06-05 |
Medich John R |
Uses and compositions for treatment of rheumatoid arthritis
|
|
US20080311043A1
(en)
|
2006-06-08 |
2008-12-18 |
Hoffman Rebecca S |
Uses and compositions for treatment of psoriatic arthritis
|
|
US20100021451A1
(en)
|
2006-06-08 |
2010-01-28 |
Wong Robert L |
Uses and compositions for treatment of ankylosing spondylitis
|
|
CN103316402A
(zh)
|
2006-06-30 |
2013-09-25 |
艾伯维生物技术有限公司 |
自动注射装置
|
|
WO2008031013A1
(en)
|
2006-09-08 |
2008-03-13 |
Gene Logic Inc. |
Method for treating inflammatory diseases of the digestive tract
|
|
BRPI0716762A2
(pt)
|
2006-09-13 |
2013-09-24 |
Abbott Lab |
melhorias da cultura celular
|
|
NZ576133A
(en)
|
2006-10-27 |
2012-10-26 |
Abbott Biotech Ltd |
Crystalline anti-htnfalpha antibodies
|
|
MX2009010361A
(es)
|
2007-03-29 |
2009-10-16 |
Abbott Lab |
Anticuerpos il-12 anti-humanos cristalinos.
|
|
WO2008150491A2
(en)
|
2007-05-31 |
2008-12-11 |
Abbott Laboratories |
BIOMARKERS PREDICTIVE OF THE RESPONSIVENESS TO TNFα INHIBITORS IN AUTOIMMUNE DISORDERS
|
|
EP2152318A4
(en)
|
2007-06-01 |
2011-12-07 |
Abbott Biotech Ltd |
COMPOSITIONS AND USES FOR THE TREATMENT OF PSORIASIS AND CROHN'S DISEASE
|
|
WO2008154543A2
(en)
|
2007-06-11 |
2008-12-18 |
Abbott Biotechnology Ltd. |
Methods for treating juvenile idiopathic arthritis
|
|
EP2173380A4
(en)
|
2007-07-13 |
2011-08-31 |
Abbott Biotech Ltd |
METHOD AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa HEMMER
|
|
WO2009020654A1
(en)
|
2007-08-08 |
2009-02-12 |
Abbott Laboratories |
Compositions and methods for crystallizing antibodies
|
|
WO2009032128A1
(en)
|
2007-08-28 |
2009-03-12 |
Abbott Biotechnology Ltd. |
Compositions and methods comprising binding proteins for adalimumab
|
|
NZ622583A
(en)
|
2007-11-30 |
2015-08-28 |
Abbvie Biotechnology Ltd |
Protein formulations and methods of making same
|
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
|
CN101965514A
(zh)
|
2008-01-03 |
2011-02-02 |
艾博特生物技术有限公司 |
预测化合物在治疗银屑病中的长期功效
|
|
BRPI0907186A2
(pt)
|
2008-01-15 |
2015-07-14 |
Abbott Gmbh & Co Kg |
Composições proteicas pulverizadas e métodos para sua produção
|
|
NZ600979A
(en)
|
2008-01-15 |
2014-01-31 |
Abbott Lab |
Improved mammalian expression vectors and uses thereof
|
|
JP2011511777A
(ja)
|
2008-01-30 |
2011-04-14 |
アボット・ラボラトリーズ |
抗体断片を結晶化するための組成物及び方法
|
|
US20100040630A1
(en)
|
2008-03-24 |
2010-02-18 |
Aake Elden |
Methods and compositions for treating bone loss
|
|
CN102458517B
(zh)
|
2009-04-29 |
2014-07-23 |
阿布维生物技术有限公司 |
自动注射装置
|
|
RU2560701C2
(ru)
|
2009-05-04 |
2015-08-20 |
Эббви Байотекнолоджи Лтд. |
Стабильные композиции с высокими концентрациями белков антител человека против tnf-альфа
|
|
EP2531613A2
(en)
|
2010-02-02 |
2012-12-12 |
Abbott Biotechnology Ltd. |
Methods and compositions for predicting responsiveness to treatment with tnf-alpha inhibitor
|
|
HUE039740T2
(hu)
|
2010-06-03 |
2019-01-28 |
Abbvie Biotechnology Ltd |
Alkalmazások és készítmények hidradenitis suppurativa (HS) kezelésére
|
|
AU2011325974B2
(en)
|
2010-11-11 |
2016-10-27 |
Abbvie Biotechnology Ltd. |
Improved high concentration anti-TNFalpha antibody liquid formulations
|